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COMPARING THE NEUROTOXICITY OF THE CANCER
DRUGS CISPLATIN AND OXALIPLATIN

Dan Barkmeier and Anthony Windebank*
Department of Biology, Illinois Wesleyan University
Department of Molecular Neuroscience, Mayo Clinic

Cisplatin is a platinum-based drug that has been used to successfully treat cancer since
the 1970s, especially testicular and ovarian cancer. Cisplatin acts by binding to DNA and
interfering with DNA replication, which most significantly affects rapidly dividing cells
like cancer. However, the dosage that can be given to patients is limited by cisplatin's
damage to the dorsal root ganglia, which are responsible for somatic sensory. A variety
of similar platinum drugs have therefore been tested for less damaging neurotoxicity
profiles. One of these compounds, oxaliplatin, was recently approved for treatment of
colorectal cancer. Relatively little is known about its exact mechanism of action and
neurotoxicity though. The goal of this project was to compare the neurotoxicity of
cisplatin versus oxaliplatin and to further characterize the mechanism of oxaliplatin
action. Results are not definite yet, but oxaliplatin causes apoptosis just like cisplatin,
seems to cause less neuron cell death at equimolar concentrations, and both binds to and
releases from neuron cell DNA more slowly than cisplatin.

